Bioluminescence imaging enhances analysis of drug responses in a patient-derived xenograft model of pediatric ALL

Luke Jones, Jennifer Richmond, Kathryn Evans, Hernan Carol, Duohui Jing, Raushan T. Kurmasheva, Catherine A. Billups, Peter J Houghton, Malcolm A. Smith, Richard B. Lock

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: Robust preclinical models of pediatric acute lymphoblastic leukemia (ALL) are essential in prioritizing promising therapies for clinical assessment in high-risk patients. Patient-derived xenograft (PDX) models of ALL provide a clinically relevant platform for assessing novel drugs, with efficacy generally assessed by enumerating circulating human lymphoblasts in mouse peripheral blood (PB) as an indicator of disease burden. While allowing indirect measurement of disease burden in real time, this technique cannot assess treatment effects on internal reservoirs of disease. We explore benefits of bioluminescence imaging (BLI) to evaluate drug responses in ALL PDXs, compared with PB monitoring. BLI-based thresholds of drug response are also explored. Experimental Design: ALL PDXs were lentivirally transduced to stably express luciferase and green fluorescent protein. In vivo PDX responses to an induction-type regimen of vincristine, dexamethasone, and L-asparaginase were assessed by BLI and PB. Residual disease at day 28 after treatment initiation was assessed by flow cytometric analysis of major organs. BLI and PB were subsequently used to evaluate efficacy of the Bcl-2 inhibitor venetoclax. Results: BLI considerably accelerated and enhanced detection of leukemia burden compared with PB and identified sites of residual disease during treatment in a quantitative manner, highlighting limitations in current PB-based scoring criteria. Using BLI alongside enumeration of human lymphoblasts in PB and bone marrow, we were able to redefine response criteria analogous to the clinical setting. Conclusions: BLI substantially improves the stringency of preclinical drug testing in pediatric ALL PDXs, which will likely be important in prioritizing effective agents for clinical assessment.

Original languageEnglish (US)
Pages (from-to)3744-3755
Number of pages12
JournalClinical Cancer Research
Volume23
Issue number14
DOIs
StatePublished - Jul 15 2017

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Heterografts
Pediatrics
Pharmaceutical Preparations
Disease Reservoirs
Asparaginase
Vincristine
Therapeutics
Green Fluorescent Proteins
Luciferases
Dexamethasone
Leukemia
Research Design
Bone Marrow

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jones, L., Richmond, J., Evans, K., Carol, H., Jing, D., Kurmasheva, R. T., ... Lock, R. B. (2017). Bioluminescence imaging enhances analysis of drug responses in a patient-derived xenograft model of pediatric ALL. Clinical Cancer Research, 23(14), 3744-3755. https://doi.org/10.1158/1078-0432.CCR-16-2392

Bioluminescence imaging enhances analysis of drug responses in a patient-derived xenograft model of pediatric ALL. / Jones, Luke; Richmond, Jennifer; Evans, Kathryn; Carol, Hernan; Jing, Duohui; Kurmasheva, Raushan T.; Billups, Catherine A.; Houghton, Peter J; Smith, Malcolm A.; Lock, Richard B.

In: Clinical Cancer Research, Vol. 23, No. 14, 15.07.2017, p. 3744-3755.

Research output: Contribution to journalArticle

Jones, L, Richmond, J, Evans, K, Carol, H, Jing, D, Kurmasheva, RT, Billups, CA, Houghton, PJ, Smith, MA & Lock, RB 2017, 'Bioluminescence imaging enhances analysis of drug responses in a patient-derived xenograft model of pediatric ALL', Clinical Cancer Research, vol. 23, no. 14, pp. 3744-3755. https://doi.org/10.1158/1078-0432.CCR-16-2392
Jones, Luke ; Richmond, Jennifer ; Evans, Kathryn ; Carol, Hernan ; Jing, Duohui ; Kurmasheva, Raushan T. ; Billups, Catherine A. ; Houghton, Peter J ; Smith, Malcolm A. ; Lock, Richard B. / Bioluminescence imaging enhances analysis of drug responses in a patient-derived xenograft model of pediatric ALL. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 14. pp. 3744-3755.
@article{0a707afe88ee4dc18be730291ec5b294,
title = "Bioluminescence imaging enhances analysis of drug responses in a patient-derived xenograft model of pediatric ALL",
abstract = "Purpose: Robust preclinical models of pediatric acute lymphoblastic leukemia (ALL) are essential in prioritizing promising therapies for clinical assessment in high-risk patients. Patient-derived xenograft (PDX) models of ALL provide a clinically relevant platform for assessing novel drugs, with efficacy generally assessed by enumerating circulating human lymphoblasts in mouse peripheral blood (PB) as an indicator of disease burden. While allowing indirect measurement of disease burden in real time, this technique cannot assess treatment effects on internal reservoirs of disease. We explore benefits of bioluminescence imaging (BLI) to evaluate drug responses in ALL PDXs, compared with PB monitoring. BLI-based thresholds of drug response are also explored. Experimental Design: ALL PDXs were lentivirally transduced to stably express luciferase and green fluorescent protein. In vivo PDX responses to an induction-type regimen of vincristine, dexamethasone, and L-asparaginase were assessed by BLI and PB. Residual disease at day 28 after treatment initiation was assessed by flow cytometric analysis of major organs. BLI and PB were subsequently used to evaluate efficacy of the Bcl-2 inhibitor venetoclax. Results: BLI considerably accelerated and enhanced detection of leukemia burden compared with PB and identified sites of residual disease during treatment in a quantitative manner, highlighting limitations in current PB-based scoring criteria. Using BLI alongside enumeration of human lymphoblasts in PB and bone marrow, we were able to redefine response criteria analogous to the clinical setting. Conclusions: BLI substantially improves the stringency of preclinical drug testing in pediatric ALL PDXs, which will likely be important in prioritizing effective agents for clinical assessment.",
author = "Luke Jones and Jennifer Richmond and Kathryn Evans and Hernan Carol and Duohui Jing and Kurmasheva, {Raushan T.} and Billups, {Catherine A.} and Houghton, {Peter J} and Smith, {Malcolm A.} and Lock, {Richard B.}",
year = "2017",
month = "7",
day = "15",
doi = "10.1158/1078-0432.CCR-16-2392",
language = "English (US)",
volume = "23",
pages = "3744--3755",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Bioluminescence imaging enhances analysis of drug responses in a patient-derived xenograft model of pediatric ALL

AU - Jones, Luke

AU - Richmond, Jennifer

AU - Evans, Kathryn

AU - Carol, Hernan

AU - Jing, Duohui

AU - Kurmasheva, Raushan T.

AU - Billups, Catherine A.

AU - Houghton, Peter J

AU - Smith, Malcolm A.

AU - Lock, Richard B.

PY - 2017/7/15

Y1 - 2017/7/15

N2 - Purpose: Robust preclinical models of pediatric acute lymphoblastic leukemia (ALL) are essential in prioritizing promising therapies for clinical assessment in high-risk patients. Patient-derived xenograft (PDX) models of ALL provide a clinically relevant platform for assessing novel drugs, with efficacy generally assessed by enumerating circulating human lymphoblasts in mouse peripheral blood (PB) as an indicator of disease burden. While allowing indirect measurement of disease burden in real time, this technique cannot assess treatment effects on internal reservoirs of disease. We explore benefits of bioluminescence imaging (BLI) to evaluate drug responses in ALL PDXs, compared with PB monitoring. BLI-based thresholds of drug response are also explored. Experimental Design: ALL PDXs were lentivirally transduced to stably express luciferase and green fluorescent protein. In vivo PDX responses to an induction-type regimen of vincristine, dexamethasone, and L-asparaginase were assessed by BLI and PB. Residual disease at day 28 after treatment initiation was assessed by flow cytometric analysis of major organs. BLI and PB were subsequently used to evaluate efficacy of the Bcl-2 inhibitor venetoclax. Results: BLI considerably accelerated and enhanced detection of leukemia burden compared with PB and identified sites of residual disease during treatment in a quantitative manner, highlighting limitations in current PB-based scoring criteria. Using BLI alongside enumeration of human lymphoblasts in PB and bone marrow, we were able to redefine response criteria analogous to the clinical setting. Conclusions: BLI substantially improves the stringency of preclinical drug testing in pediatric ALL PDXs, which will likely be important in prioritizing effective agents for clinical assessment.

AB - Purpose: Robust preclinical models of pediatric acute lymphoblastic leukemia (ALL) are essential in prioritizing promising therapies for clinical assessment in high-risk patients. Patient-derived xenograft (PDX) models of ALL provide a clinically relevant platform for assessing novel drugs, with efficacy generally assessed by enumerating circulating human lymphoblasts in mouse peripheral blood (PB) as an indicator of disease burden. While allowing indirect measurement of disease burden in real time, this technique cannot assess treatment effects on internal reservoirs of disease. We explore benefits of bioluminescence imaging (BLI) to evaluate drug responses in ALL PDXs, compared with PB monitoring. BLI-based thresholds of drug response are also explored. Experimental Design: ALL PDXs were lentivirally transduced to stably express luciferase and green fluorescent protein. In vivo PDX responses to an induction-type regimen of vincristine, dexamethasone, and L-asparaginase were assessed by BLI and PB. Residual disease at day 28 after treatment initiation was assessed by flow cytometric analysis of major organs. BLI and PB were subsequently used to evaluate efficacy of the Bcl-2 inhibitor venetoclax. Results: BLI considerably accelerated and enhanced detection of leukemia burden compared with PB and identified sites of residual disease during treatment in a quantitative manner, highlighting limitations in current PB-based scoring criteria. Using BLI alongside enumeration of human lymphoblasts in PB and bone marrow, we were able to redefine response criteria analogous to the clinical setting. Conclusions: BLI substantially improves the stringency of preclinical drug testing in pediatric ALL PDXs, which will likely be important in prioritizing effective agents for clinical assessment.

UR - http://www.scopus.com/inward/record.url?scp=85024128971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024128971&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-2392

DO - 10.1158/1078-0432.CCR-16-2392

M3 - Article

C2 - 28119366

AN - SCOPUS:85024128971

VL - 23

SP - 3744

EP - 3755

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 14

ER -